| Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer C Schaake-Koning, W Van den Bogaert, O Dalesio, J Festen, ... New England Journal of Medicine 326 (8), 524-530, 1992 | 1618 | 1992 |
| K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung RJC Slebos, RE Kibbelaar, O Dalesio, A Kooistra, J Stam, CJLM Meijer, ... New England Journal of Medicine 323 (9), 561-565, 1990 | 997 | 1990 |
| Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer JP Van Meerbeeck, GWPM Kramer, PEY Van Schil, C Legrand, EF Smit, ... Journal of the National Cancer Institute 99 (6), 442-450, 2007 | 801 | 2007 |
| Mutational activation of the K-ras oncogene S Rodenhuis, ML van de Wetering, WJ Mooi, SG Evers, N van Zandwijk, ... New England Journal of Medicine 317 (15), 929-935, 1987 | 668 | 1987 |
| Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study N Van Zandwijk, N Pavlakis, SC Kao, A Linton, MJ Boyer, S Clarke, ... The Lancet Oncology 18 (10), 1386-1396, 2017 | 599 | 2017 |
| Circulating microRNAs: Association with disease and potential use as biomarkers G Reid, MB Kirschner, N van Zandwijk Critical reviews in oncology/hematology 80 (2), 193-208, 2011 | 592 | 2011 |
| Haemolysis during sample preparation alters microRNA content of plasma MB Kirschner, SC Kao, JJ Edelman, NJ Armstrong, MP Vallely, ... PloS one 6 (9), e24145, 2011 | 589 | 2011 |
| Integrative molecular characterization of malignant pleural mesothelioma J Hmeljak, F Sanchez-Vega, KA Hoadley, J Shih, C Stewart, D Heiman, ... Cancer discovery 8 (12), 1548-1565, 2018 | 513 | 2018 |
| EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer N Van Zandwijk, O Dalesio, U Pastorino, N de Vries, H van Tinteren Journal of the National Cancer Institute 92 (12), 977-986, 2000 | 487 | 2000 |
| Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer U Gatzemeier, G Groth, C Butts, N Van Zandwijk, F Shepherd, A Ardizzoni, ... Annals of oncology 15 (1), 19-27, 2004 | 465 | 2004 |
| Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes T Le Chevalier, G Scagliotti, R Natale, S Danson, R Rosell, R Stahel, ... Lung cancer 47 (1), 69-80, 2005 | 407 | 2005 |
| The impact of hemolysis on cell-free microRNA biomarkers MB Kirschner, JJB Edelman, SCH Kao, MP Vallely, N Van Zandwijk, ... Frontiers in genetics 4, 94, 2013 | 390 | 2013 |
| Photodynamic therapy: a promising new modality for the treatment of cancer JJ Schuitmaker, P Baas, H Van Leengoed, FW Van der Meulen, WM Star, ... Journal of Photochemistry and Photobiology B: Biology 34 (1), 3-12, 1996 | 379 | 1996 |
| High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy SCH Kao, N Pavlakis, R Harvie, JL Vardy, MJ Boyer, N van Zandwijk, ... Clinical cancer research 16 (23), 5805-5813, 2010 | 363 | 2010 |
| Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment … G Giaccone, TA Splinter, C Debruyne, GS Kho, P Lianes, N Van Zandwijk, ... Journal of clinical oncology 16 (6), 2133-2141, 1998 | 344 | 1998 |
| Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non … CJ Hoekstra, SG Stroobants, EF Smit, J Vansteenkiste, H Van Tinteren, ... Journal of clinical oncology 23 (33), 8362-8370, 2005 | 319 | 2005 |
| Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers CAL Ruivenkamp, T van Wezel, C Zanon, APM Stassen, C Vlcek, ... Nature genetics 31 (3), 295-300, 2002 | 306 | 2002 |
| Guidelines for the diagnosis and treatment of malignant pleural mesothelioma N Van Zandwijk, C Clarke, D Henderson, AW Musk, K Fong, A Nowak, ... Journal of thoracic disease 5 (6), E254, 2013 | 280 | 2013 |
| Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma G Reid, ME Pel, MB Kirschner, YY Cheng, N Mugridge, J Weiss, ... Annals of Oncology 24 (12), 3128-3135, 2013 | 278 | 2013 |
| Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer … G Giaccone, A Ardizzoni, A Kirkpatrick, M Clerico, T Sahmoud, ... Journal of clinical oncology 14 (3), 814-820, 1996 | 264 | 1996 |
